Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
65 Results for "
Aβ-aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (65)
65 Results for "Aβ-aggregation" in MCE Product Catalog:
Category:
Alkaloids Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Plants Annonaceae Isoquinoline Alkaloids
Target:
Cat. No.: HY-146142
CAS No.: 1946008-31-6
Target:
Research Areas:
AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and BuChE inhibitor with IC50 values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced β-amyloid (Aβ) aggregation inhibition with an IC50 of 62.52 μM. AChE/BuChE-IN-2 can cross the BBB .
Cat. No.: HY-176254
Target:
Research Areas:
LSD1-IN-43 is a highly selective, reversible, orally active and brain-penetrant LSD1 inhibitor with an IC50 value of 0.8 μM. LSD1-IN-43 has low inhibitory activity against MAO-A and MAO-B, two homologs of LSD1. LSD1-IN-43 significantly inhibits Aβ aggregation and enhances Aβ-induced neuronal cell viability. LSD1-IN-43 can be used for the study of Alzheimer’s disease (AD).
Cat. No.: HY-180160
Target:
Research Areas:
Aβ aggregation-IN-3 (Compound B7) is an Aβ aggregation inhibitor. Aβ aggregation-IN-3 inhibits Aβ aggregation. Aβ aggregation-IN-3 confers protection in both neuronal and microglial models. Aβ aggregation-IN-3 reduces Aβ-induced paralysis in C. elegans. Aβ aggregation-IN-3 improves Alzheimer's disease .
Cat. No.: HY-180997
Target:
Research Areas:
Aβ aggregation-IN-5 is a brain-penetrant amyloid-β aggregation inhibitor. Aβ aggregation-IN-5 inhibits Aβ aggregation/oligomerization, rescues cells from AB/ROS toxicity and reduces microglial activation/NO production. Aβ aggregation-IN-5 reduces amyloid burden, neuroinflammation, microglial activation in APP/PSEN1 mice. Aβ aggregation-IN-5 can be used for the research of Alzheimer's disease .
Cat. No.: HY-123745
CAS No.: 439932-74-8
Target:
Research Areas:
Aβ aggregation-IN-6 is an Aβ aggregation inhibitor with ~60-70% inhibition of Aβ17-40 aggregation. Aβ aggregation-IN-6 stabilizes Aβ dimer assembly, binds to Aβ steric-zipper assembly. Aβ aggregation-IN-6 can be used for the research of alzheimer's disease .
Cat. No.: HY-147820
CAS No.: 2559709-99-6
Target:
Research Areas:
AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity .
Cat. No.: HY-149583
Target:
Research Areas:
Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation .
Cat. No.: HY-176439
CAS No.: 2758789-03-4
Target:
Research Areas:
AChE-IN-88 (Compound 26) is a novel pyridazine derivative. AChE-IN-88 is an orally active multi-target ligand for Alzheimer's disease (AD) that inhibits both acetylcholinesterase (AChE) and amyloid β protein (Aβ) aggregation (pIC50: 7.16) .
Cat. No.: HY-163320
CAS No.: 181114-32-9
Target:
Research Areas:
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .
Cat. No.: HY-147980
CAS No.: 2417977-65-0
Target:
Research Areas:
Aβ-IN-5 (Compound e12) is an orally active Aβ aggregation inhibitor. Aβ-IN-5 also inhibits AChE and BuChE with IC50 values of 21.29 μM and 1.32 μM, respectively. Aβ-IN-5 shows excellent neuroprotective effects and low neurotoxicity .
Cat. No.: HY-155305
Research Areas:
BuChE-IN-9 (compound 22a) is a potent equine serum-derived BuChE (eqBuChE) inhibitor with an IC50 of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties .
Cat. No.: HY-157441
Target:
Research Areas:
AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC50 values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease .
Cat. No.: HY-162832
Target:
Research Areas:
Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ42, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects .
Cat. No.: HY-147938
CAS No.: 2742707-36-2
Target:
Research Areas:
AChE-IN-19 (compound A15) is a highly potent AChE inhibitor with an IC50 value of 0.56 μM, also inhibits Aβ aggregation. AChE-IN-19 has potent neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE-IN-19 can be used for researching Alzheimer's disease .
Cat. No.: HY-149582
CAS No.: 69791-41-9
Target:
Research Areas:
Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .
Cat. No.: HY-14535
CAS No.: 956128-01-1
Target:
Research Areas:
SEN-1269 is a potent Aβ aggregation inhibitor. SEN-1269 blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). SEN-1269 reduces the deficits in LTP and memory induced by Aβ oligomers. SEN-1269 can be used for the research of Alzheimer's disease .
Cat. No.: HY-146347
CAS No.: 2376710-36-8
Target:
Research Areas:
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC50 of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .
Cat. No.: HY-149984
CAS No.: 2956426-18-7
Target:
Research Areas:
MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model .
Cat. No.: HY-157440
Research Areas:
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
